A Center of Excellence (COE) has been set up in the UK to study vaccine-preventable diseases.
Funded by coronavirus vaccine maker Pfizer, the group is the second in a global network of locations – and the first outside of the United States.
The Pfizer Center of Excellence in the Epidemiology of Vaccine Preventable Diseases, based at Bristol University, will conduct research to support the design, development and use of next generation vaccines.
The pharmaceutical company said it initially invested £ 4.6 million in the COE to conduct surveillance studies in hospitals and in the community to “identify and measure exposure to certain vaccine-preventable infectious diseases, including adults older people as well as children are affected ”. .
The center is led by Adam Finn, Professor of Pediatrics at the University, Director of the Bristol Vaccine Center and Head of Bristol UNCOVER (Bristol COVID Emergency Research Group).
Health Secretary Matt Hancock visited the center’s research labs today (Tuesday May 25) to meet virologists Dr. Andrew Davidson and Dr. Meet David Matthews.
At the start of the Covid-19 pandemic, the two doctors were the only team at a UK university working with worrying “live” human coronaviruses and the first UK team to do research on the live human SARS-CoV-2 virus in published a controlled laboratory
Professor Hugh Brady, Vice Chancellor and President of the University, said, “We are honored to be selected by Pfizer as one of its global vaccine COEs.
“Bristol’s expertise and collaboration with two NHS trusts and other health partners make Bristol a unique place to conduct world-class vaccine research.
“This partnership is not only an important milestone in Bristol’s role in improving global public health, but it also builds on our region’s historical heritage in public health, public health and vaccine research.”
Dr. Luis Jodar, Pfizer’s chief vaccines president and chief medical officer, vaccines, said the investment shows the pharmaceutical company’s “continued commitment to Britain’s thriving life science sector.”
“Well-conducted adult clinical population epidemiological research studies are a critical component to better understanding the role that direct and potentially indirect effects of vaccination can play in reducing the effects and consequences of infectious diseases – findings that may be more valuable than ever against the backdrop of this terrible pandemic, ”he said.
Professor Adam Finn said, “A global research effort is needed to better define and understand vaccine preventable diseases and the effectiveness of vaccines.
“I am very proud to be part of this new partnership at a time when it has never been more important for industry and science to work together to overcome the plight of infectious diseases.”
Pfizer’s first COE location opened in 2020 at the University of Louisville, Kentucky, USA.